Although Infinity Pharmaceuticals Inc. CEO Adelene Perkins said her firm's "going-in assumption is that we will be successful" in selling rights to phosphoinositide 3-kinase (PI3K) inhibitor duvelisib, Abbvie Inc.'s decision to pull out of their partnership undoubtedly threw cold water on the class.